Endogenex Stock
Endogenex develops endoscopic therapies designed to treat metabolic diseases, with a focus on Type 2 diabetes. Its flagship solution, the ReCET System, uses catheter-based therapy to remodel duodenal tissue and improve metabolic function without invasive surgery.
For more Endogenex stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Stacey Pugh Chief Executive Officer |
| Krissy Wright Chief Financial Officer |
| Chris Sorli, MD Chief Medical Officer |
